MediPharm Labs (TSE:LABS) Director Christopher David Taves Sells 176,786 Shares

MediPharm Labs Corp. (TSE:LABS) Director Christopher David Taves sold 176,786 shares of the stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of C$0.08, for a total transaction of C$14,142.88. Following the transaction, the director owned 2,847,939 shares in the company, valued at approximately C$227,835.12. The trade was a 5.84% decrease in their ownership of the stock.

MediPharm Labs Price Performance

Shares of LABS remained flat at C$0.07 during mid-day trading on Friday. 75,364 shares of the company traded hands, compared to its average volume of 237,688. The business has a fifty day moving average of C$0.07 and a 200-day moving average of C$0.07. The company has a current ratio of 3.02, a quick ratio of 3.10 and a debt-to-equity ratio of 0.05. MediPharm Labs Corp. has a twelve month low of C$0.06 and a twelve month high of C$0.10. The company has a market cap of C$29.74 million, a PE ratio of -3.50 and a beta of -0.61.

MediPharm Labs Company Profile

Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API), and advanced derivative products produced in a GMP-certified facility with ISO-standard clean rooms. MediPharm has invested in an expert research-driven team, state-of-the-art technology, advanced purification methodologies, and purpose-built facilities to deliver pure, trusted, precision-dosed cannabinoid products for domestic and international markets.